nach oben

Clinical Pharmacokinetics

Erschienen in:

01.12.2005 | Original Research Article

Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies

Erschienen in: Clinical Pharmacokinetics | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To: (i) test different pharmacokinetic models to fit full tacrolimus concentration-time profiles; (ii) estimate the tacrolimus pharmacokinetic characteristics in stable lung transplant patients with or without cystic fibrosis (CF); (iii) compare the pharmacokinetic parameters between these two patient groups; and (iv) design maximum a posteriori Bayesian estimators (MAP-BE) for pharmacokinetic forecasting in these patients using a limited sampling strategy.

Methods

Tacrolimus blood concentration-time profiles obtained on three occasions within a 5-day period in 22 adult lung transplant recipients (11 with CF and 11 without CF) were retrospectively studied. Three different one-compartment models with first-order elimination were tested to fit the data: one with first-order absorption, one convoluted with a gamma distribution to describe the absorption phase, and one convoluted with a double gamma distribution able to describe secondary concentration peaks. Finally, Bayesian estimation using the best model and a limited sampling strategy was tested in the two groups of patients for its ability to provide accurate estimates of the main tacrolimus pharmacokinetic parameters and exposure indices.

Results

The one-compartment model with first-order elimination convoluted with a double gamma distribution gave the best results in both CF and non-CF lung transplant recipients. The patients with CF required higher doses of tacrolimus than those without CF to achieve similar drug exposure, and population modelling had to be performed in CF and non-CF patients separately. Accurate Bayesian estimates of area under the blood concentration-time curve from 0 to 12 hours (AUC₁₂), AUC from 0 to 4 hours, peak blood concentration (C_max) and time to reach C_max were obtained using three blood samples collected at 0, 1 and 3 hours in non-CF patients (correlation coefficient between observed and estimated AUC₁₂, R² = 0.96), and at 0, 1.5 and 4 hours in CF patients (R² = 0.91).

Conclusion

A particular pharmacokinetic model was designed to fit the complex and highly variable tacrolimus blood concentration-time profiles. Moreover, MAP-BE allowing tacrolimus therapeutic drug monitoring based on AUC₁₂ were developed.

Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746–94PubMedCrossRef

Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247–97PubMedCrossRef

Hertz MI, Taylor DO, Trulock EP, et al. The registry of the International Society for Heart and Lung Transplantation: 19th official report, 2002. J Heart Lung Transplant 2002; 21: 950–70PubMedCrossRef

McCurry KR, Zaldonis DB, Keenan RJ, et al. Long term follow-up of a prospective randomised trial of tacrolimus versus cyclosporine in human lung transplantation [abstract]. Am J Transplant 2002; 2 Suppl. 3: S159

Zuckermann A, Reichenspurner H, Jacksch P, et al. Long term follow-up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. J Heart Lung Transplant 2003; 22 Suppl. 1: S76–7CrossRef

Treede H, Reichenspurner H, Meiser B, et al. Influence of four different immunosuppressive protocols on acute and chronic rejection (BOS) after lung transplantation: experience in 120 patients [abstract]. J Heart Lung Transplant 2001; 20: 176PubMedCrossRef

Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20: 511–7PubMedCrossRef

Roman A, Bravo C, Monforte V, et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. Transplant Proc 2002; 34: 146–7PubMedCrossRef

Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21: 435–9PubMedCrossRef

10.

Fieguth H, Krueger S, Wiedenmann D, et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. Transplant Proc 2002; 34: 1884–9PubMedCrossRef

11.

Verderlen GM, Buyse B, Delcroix M, et al. Changing cyclosporine to tacrolimus after lung transplantation: reasons and outcome [abstract]. Eur Respir J 2000; 16 Suppl. 1: S510

12.

Klepetko W, Sarahrudi K, Corris P, et al. Efficacy of conversion from cyclosporin A to tacrolimus in lung transplantation [abstract]. Am J Transplant 2002; 2 Suppl. 3: S159

13.

Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosupressant drugs in clinical practice. Clin Ther 2002; 24: 330–50PubMedCrossRef

14.

Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001; 57: 479–84PubMedCrossRef

15.

Staatz CE, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130–7PubMedCrossRef

16.

Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 70: 660–9CrossRef

17.

Zahir H. MacLachlan AJ, Nelson A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 2005; 27(4): 422–30PubMedCrossRef

18.

Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 2005; 61(5-6): 409–16PubMedCrossRef

19.

Macchi-Andanson M, Charpiat Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129–33PubMedCrossRef

20.

Fukudo M, Yano I, Fukatsu S, et al. Forecasting of blood concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet 2003; 42: 1161–78PubMedCrossRef

21.

Willis C, Staatz CE, Tett SE. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric and adult renal transplant patients. Ther Drug Monit 2003; 25: 158–66PubMedCrossRef

22.

Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40: 375–82PubMedCrossRef

23.

Léger F, Debord J, Le Meur Y, et al. Maximum a posteriori bayesian estimation of oral cyclosporine pharmacokinetics in stable renal transplant patients. Clin Pharmacokinet 2002; 41: 71–80PubMedCrossRef

24.

Monchaud C, Léger F, Rousseau A, et al. Bayesian forecasting of oral cyclosporine in cardiac transplant recipients. Eur J Clin Pharmacol 2003; 58: 813–20PubMed

25.

Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003; 25: 28–35PubMedCrossRef

26.

Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control 1974; 19: 716–23CrossRef

27.

D’argenio DZ. Optimal sampling times for pharmacokinetics experiments. J Pharmacokinet Biopharm 1981; 9: 739–5PubMed

28.

Staatz CE, Tett SE. Clinical phamacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43(10): 623–53PubMedCrossRef

29.

Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–80PubMed

30.

Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69(5): 308–16PubMedCrossRef

31.

Susanto M, Benet LZ. Can enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport. Pharm Res 2002; 19(4): 457–62PubMedCrossRef

32.

Morton JM, Kear M, Williamson S, et al. Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation. J Heart Lung Transplant 2002; 21: 143–4CrossRef

Titel: Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies
Publikationsdatum: 01.12.2005
Erschienen in: Clinical Pharmacokinetics / Ausgabe 12/2005
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200544120-00010

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2005

Population Pharmacokinetics of Onercept in Healthy Subjects

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

Population Pharmacokinetics of Olmesartan Following Oral Administration of its Prodrug, Olmesartan Medoxomil

Clinical Pharmacology of Lumiracoxib

Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers

Penetration of Orally Administered Prulifloxacin Into Human Lung Tissue